Home / Recalls / Harbin Jixianglong Biotech Co., Ltd. / D-0380-2026

D-0380-2026 Class II Ongoing

Recalled by Harbin Jixianglong Biotech Co., Ltd. — Haerbin, N/A

Recall Details

Product Type: Drugs
Report Date: March 11, 2026
Initiation Date: February 13, 2026
Termination Date: N/A
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: N/A

Product Description

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.

Reason for Recall

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Distribution Pattern

Nationwide within the United States

Code Information

Batch # CP-030-20250911, Mfg Date: Sep. 25th, 2025, Retest Date: Sep. 24th, 2027.